Research U.S. Registry Data Confirm Liver Risk With Controversial Vasculitis DrugBy Healthcare Propulsion StaffAugust 25, 20260 The C5a complement inhibitor avacopan (Tavneos) was FDA-approved in 2021 to treat ANCA-associated vasculitis, but questions have been raised about…
